> Research Use Only (RUO): Matrixyl (Palmitoyl Pentapeptide-4) is a research compound intended exclusively for laboratory investigation. All content below is educational and not a guide for human or animal use.
---
What Is Matrixyl (Palmitoyl Pentapeptide-4)?
Palmitoyl pentapeptide-4 — trademarked as Matrixyl® and documented in cosmetic ingredient nomenclature as Pal-KTTKS — is a lipopeptide derived from a procollagen type I propeptide fragment. It consists of a five-amino-acid sequence (Lys-Thr-Thr-Lys-Ser, or KTTKS) covalently linked at its N-terminus to a 16-carbon palmitic acid chain.
The parent pentapeptide KTTKS corresponds to residues 147–151 of the type I procollagen α1 chain, placing it squarely within a class of bioactive molecules known as matrikines — short peptide fragments liberated from extracellular matrix (ECM) proteins during physiological remodeling that function as signaling molecules to regulate matrix biosynthesis. The palmitoyl modification was engineered by Sederma (France) to improve dermal penetration and proteolytic stability, converting the hydrophilic KTTKS into an amphiphilic prodrug-like molecule that can partition into stratum corneum lipid bilayers and deliver the active sequence into viable skin compartments.
Nomenclature at a Glance
| Identifier | Value |
|---|---|
| INCI name | Palmitoyl Pentapeptide-4 |
| Former INCI | Palmitoyl Pentapeptide-3 (pre-2007 revision) |
| Trade name | Matrixyl® (Sederma) |
| Peptide sequence | Pal-Lys-Thr-Thr-Lys-Ser-OH |
| Abbreviation | Pal-KTTKS |
| CAS number | 214047-00-4 |
| Approximate MW | ~802 Da |
---
Structural Chemistry and the Matrikine Concept
KTTKS originates from the COOH-propeptide region of the α1 chain of procollagen type I — precisely the domain that participates in feedback regulation of collagen biosynthesis during normal tissue homeostasis. During ECM turnover, matrix metalloproteinases (MMPs) and collagenases cleave procollagen propeptides, releasing matrikine fragments that signal the biosynthetic machinery. Under conditions of photodamage or chronological aging where collagen degradation outpaces synthesis, supplementation with KTTKS is hypothesized to restore anabolic signaling in dermal fibroblasts.
The palmitoylation strategy is well-established in peptide chemistry: attachment of a 16-carbon palmitic acid chain converts a poorly permeable peptide into a lipopeptide capable of intercalating into biological membranes. Human skin permeation studies using Franzell diffusion cells demonstrated that unmodified KTTKS was not detectable in any skin compartment, while Pal-KTTKS penetrated all three layers: stratum corneum (4.2 ± 0.7 µg/cm²), epidermis (2.8 ± 0.5 µg/cm²), and dermis (0.3 ± 0.1 µg/cm²). Palmitoylation also conferred significantly greater proteolytic stability in skin homogenate preparations (Loureiro et al., Pharmaceutics, 2014).
---
Mechanism of Action
The molecular mechanism of Pal-KTTKS centers on fibroblast activation through TGF-β and growth factor receptor-mediated signaling, engaging several interlocking pathways that collectively upregulate ECM biosynthesis.
TGF-β1 Pathway Activation
KTTKS has been shown to upregulate transforming growth factor-beta 1 (TGF-β1) in dermal fibroblasts and tendon cells. A study examining KTTKS effects on tendon cell cultures demonstrated that the peptide enhanced mRNA expression of both α1(I) procollagen and TGF-β, while also stabilizing collagen mRNA through upregulation of mRNA-binding proteins (Siritapetawee et al., J Biomater Sci Polym Ed, 2007). Because TGF-β1 is the master inducer of fibroblast collagen signaling cascades, this upstream activation explains the downstream effects observed across multiple ECM protein types.
CTGF Modulation and Myofibroblast Biology
Research on wound healing contractile processes revealed that Pal-KTTKS at 0.1 µM concentrations reduces α-smooth muscle actin (α-SMA) expression and inhibits fibroblast trans-differentiation into myofibroblasts. The same study characterized effects on connective tissue growth factor (CTGF) — a downstream mediator of TGF-β signaling involved in fibrotic remodeling and wound contraction (Chantasart et al., J Cosmet Dermatol, 2019). This dual profile — stimulating constructive ECM synthesis while attenuating excessive contractile activation — positions Pal-KTTKS as a mechanistically distinct tool in both photoaging and fibrosis research.
Collagen Types I, III, IV and Fibronectin
Seminal work established that KTTKS specifically stimulates the extracellular release of collagen types I and III from fibroblasts, along with fibronectin. Collagen IV — the primary scaffolding molecule of the dermal-epidermal junction (DEJ) basement membrane — was subsequently documented in formulation studies. The stimulatory effect is concentration-dependent and is active at nanomolar to low micromolar concentrations, consistent with receptor-mediated signaling.
Elastin and Glycosaminoglycan Production
Beyond collagen, Pal-KTTKS has been associated with increased elastin fiber density and thickness, as well as enhanced synthesis of glycosaminoglycans (GAGs) including components of the hyaluronic acid matrix. These ECM scaffold elements contribute to skin hydration, elasticity, and structural resilience — all parameters that decline with chronological and UV-mediated aging.
---
Key Research Findings
Clinical Skin Research (Photoaged Tissue)
The landmark Robinson et al. (2005) investigation, published in the International Journal of Cosmetic Science, enrolled 93 women with visible facial wrinkles in a double-blind, randomized, vehicle-controlled trial. Subjects applied a Pal-KTTKS-containing moisturizer twice daily for 12 weeks. Optical profilometry and photographic image analysis showed statistically significant reductions in fine lines, wrinkles, and bumpy skin texture at both weeks 4 and 8. Histological evaluation of skin punch biopsies from treated subjects showed changes consistent with improved collagen organization and DEJ regulation (Robinson et al., Int J Cosmet Sci, 2005).
A subsequent investigation published in the Journal of the American Academy of Dermatology (JAAD) reported improvements in periorbital aging appearance with moisturizer containing palmitoyl pentapeptide applied twice daily — contributing to the early clinical evidence base for this class of signal peptides.
Permeation and Stability Studies
A comprehensive stability and permeation characterization by Loureiro et al. (2014) remains the definitive quantitative demonstration of why palmitoylation is pharmacokinetically necessary for dermal delivery of KTTKS. Using porcine ear skin as a human surrogate model and LC-MS/MS for peptide quantification, the study established:
- •Unmodified KTTKS: not detected in stratum corneum, epidermis, or dermis
- •Pal-KTTKS: distributed across all three compartments at analytically quantifiable concentrations
- •Proteolytic half-life: markedly extended for Pal-KTTKS relative to KTTKS in skin homogenate
A companion study using LC-MS/MS quantification of KTTKS in rat skin provided pharmacokinetic parameters for the peptide as an analytical standard in cutaneous metabolism research (Kaukonen et al., J Pharm Biomed Anal, 2012).
Liposomal Delivery Research (2024)
A 2024 study published in Pharmaceutics characterized liposome-encapsulated Pal-KTTKS formulations, finding that phosphatidylcholine-based liposomal delivery increased fibroblast collagen stimulation compared to equivalent concentrations of free Pal-KTTKS and ascorbic acid positive controls (Pharmaceutics, 2024). This work is directly relevant to broader nanoparticle-peptide delivery research, where controlled release kinetics can optimize tissue-level concentration-time profiles and reduce the impact of enzymatic degradation.
KTTKS Analog Development
The KTTKS scaffold has attracted significant interest from peptide chemists. A 2019 study evaluated a series of KTTKS analogs, finding that strategic amino acid substitutions modulated proteolytic stability and cytotoxicity profiles without eliminating biological activity, establishing SAR guidelines for next-generation matrikine analogs (J Pept Sci, 2019). A 2022 study explored imidazolium-based ionic liquid conjugates of pentapeptide-4, finding that these derivatives retained collagenesis-inducing activity while gaining antimicrobial properties — illustrating the versatility of the KTTKS scaffold for multifunctional peptide engineering (Molecules, 2022).
---
Comparison with Related Cosmetic Signal Peptides
Pal-KTTKS occupies a distinct position within the broader landscape of cosmetic signal peptides:
| Peptide | Mechanism | Primary Target |
|---|---|---|
| Pal-KTTKS (Matrixyl) | Matrikine → TGF-β → Collagen I/III/IV, Fibronectin | Dermal matrix scaffold |
| Acetyl Hexapeptide-3 (Argireline) | SNARE complex inhibition | Neuromuscular junction |
| Acetyl Octapeptide-3 (SNAP-8) | Extended SNARE inhibition | Neuromuscular junction |
| GHK-Cu | Copper chelation → broad ECM remodeling | Multi-target ECM + wound healing |
| Palmitoyl Tripeptide-1 (Pal-GHK) | Signal peptide → Collagen I/III/IV + decorin | Dermal scaffold + DEJ |
| Matrixyl 3000 (Pal-KTTKS + Pal-GHK) | Dual matrikine synergy | Collagen + fibronectin + GAGs |
Researchers studying cosmetic peptide mechanisms should note that Pal-KTTKS functions upstream of the ECM through TGF-β signaling, while neuromuscular peptides like Argireline act at a completely different cellular target. Their co-formulation in finished cosmetic products is mechanistically non-redundant, though the efficacy addivity of such combinations under controlled research conditions requires further characterization.
---
Matrixyl 3000 and Next-Generation Variants
Sederma subsequently developed Matrixyl 3000®, pairing Pal-KTTKS with Palmitoyl Tripeptide-1 (Pal-GHK). The rationale is mechanistic complementarity: KTTKS activates the TGF-β procollagen feedback axis while GHK acts on copper-dependent ECM enzymes including lysyl oxidase and promotes wound-healing-associated processes. A further iteration, Matrixyl Synthe'6 (Pal-GQPR), targets fibronectin and collagen VI.
From a pure research standpoint, Pal-KTTKS remains the best-characterized variant — possessing the largest body of peer-reviewed data on permeation, in vitro mechanism, and clinical imaging outcomes. Researchers designing dose-response or mechanistic experiments should use Pal-KTTKS as the reference compound before exploring multi-peptide combinations.
---
Formulation and Delivery Considerations for Research Use
Pal-KTTKS presents distinct physicochemical properties compared to fully hydrophilic peptides, requiring adapted experimental approaches.
Solubility
As an amphiphilic lipopeptide, Pal-KTTKS dissolves optimally in:
- •Dilute aqueous ethanol (50–70% ethanol): suitable for stock preparation
- •DMSO: up to ~10 mg/mL; dilute ≥100× before adding to biological systems
- •Warm aqueous buffer (pH 6–7) with brief sonication at low concentrations (<0.5 mg/mL)
- •Lipid vehicles: liposomes, microemulsions, or nanoemulsions for enhanced dispersion
At elevated aqueous concentrations, Pal-KTTKS self-associates into micelles, which can complicate dose-response interpretation. Researchers should account for critical micelle concentration (CMC) effects when designing in vitro assays.
Stability Considerations
- •Serum-containing media: esterases and lipases can cleave the palmitoyl-lysine amide bond; serum-free or low-serum conditions better preserve the intact lipopeptide
- •Proteolytic degradation: significantly slower than unmodified KTTKS, but still occurs at physiological enzyme concentrations
- •Oxidation: the serine residue can oxidize under prolonged UV exposure; store under amber glass at –20°C
Analytical Quantification
HPLC-UV at 210–220 nm provides adequate sensitivity for purity assessment of stock solutions. For quantification in biological matrices (cell supernatant, skin homogenate), LC-MS/MS with stable isotope-labeled internal standard provides the most reliable results. Published methods achieve limits of quantification in the low ng/g range for cutaneous tissue samples.
---
Research Applications
Skin Aging and Photoaging Models
The core application. Standard in vitro models use primary human dermal fibroblasts (HDFa) or NHDF cells, assessing:
- •Procollagen I C-terminal propeptide (PICP) ELISA for secreted collagen output
- •qRT-PCR for COL1A1, COL3A1, FBN1, HAS2, ELN gene expression
- •Immunofluorescence of fibronectin and collagen IV network organization
- •Western blot for TGF-β1, α-SMA, and CTGF protein levels
Wound Healing and Fibrosis Research
The documented inhibition of myofibroblast trans-differentiation and modulation of CTGF positions Pal-KTTKS as a research tool for anti-fibrotic mechanism investigation in models of skin fibrosis, keloid biology, and wound healing resolution.
Dermal-Epidermal Junction Research
Collagen IV regulation at the DEJ positions Pal-KTTKS as relevant to basement membrane integrity studies — an emerging area given DEJ deterioration as a hallmark of intrinsic aging and inflammatory skin conditions.
Tendon and Connective Tissue Biology
The Siritapetawee study demonstrated KTTKS effects in tendon fibroblast culture, extending the peptide's research relevance beyond dermis to musculoskeletal connective tissue models where collagen I regulation is equally central.
Drug Delivery and Formulation Research
As a well-characterized reference lipopeptide, Pal-KTTKS serves as an ideal model cargo for evaluating novel delivery systems: liposomes, transfersomes, solid lipid nanoparticles, polymeric nanoparticles, and ionic liquid formulations. The availability of validated LC-MS/MS quantification methods for skin tissue facilitates pharmacokinetic characterization of new delivery vehicles.
Peptide Analog and Medicinal Chemistry Research
The established structure-activity relationships of the KTTKS scaffold — identifying which residues are essential for TGF-β pathway activation versus which can be modified for improved stability or added functionality — make it a productive template for combinatorial peptide design.
---
Summary Table
| Parameter | Value |
|---|---|
| Class | Lipopeptide (palmitoyl signal peptide) |
| Origin | Procollagen type I propeptide fragment |
| Receptor/target | TGF-β pathway; matrikine receptor signaling |
| Primary in vitro effects | ↑ Collagen I/III/IV; ↑ Fibronectin; ↑ GAGs; ↓ α-SMA; ↑ TGF-β1 |
| Active concentration range | ~1 nM – 10 µM |
| Dermal penetration | Confirmed across all skin layers; KTTKS unmodified fails |
| Proteolytic stability | Significantly enhanced vs. unmodified KTTKS |
| Key assay types | Fibroblast PICP ELISA, qRT-PCR, skin permeation, clinical imaging |
| Research maturity | Highly characterized; extensive peer-reviewed literature base |
---
References
1. Robinson LR et al. Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. Int J Cosmet Sci. 2005;27(3):155-60. PubMed 18492182
2. Loureiro A et al. Dermal Stability and In Vitro Skin Permeation of Collagen Pentapeptides (KTTKS and palmitoyl-KTTKS). Pharmaceutics. 2014;6(3):515-535. PubMed 25143811
3. Siritapetawee J et al. The pentapeptide KTTKS promoting the expressions of type I collagen and transforming growth factor-beta of tendon cells. J Biomater Sci Polym Ed. 2007;18(7):855-65. PubMed 17593541
4. Chantasart D et al. Effect of Palmitoyl-Pentapeptide (Pal-KTTKS) on Wound Contractile Process in Relation with Connective Tissue Growth Factor and α-Smooth Muscle Actin Expression. J Cosmet Dermatol. 2019. PubMed 30603464
5. Topically applied KTTKS: a review. 2011. PubMed 21535443
6. Liposome Encapsulation of Pal-KTTKS. Pharmaceutics. 2024. PubMed 38399273
7. Novel KTTKS Analogues — cytotoxicity and proteolytic activity. J Pept Sci. 2019. PubMed 31618846
8. Imidazolium-based ionic liquid conjugates with pentapeptide-4. Molecules. 2022. PubMed 35950860
9. LC-MS/MS stability of collagen pentapeptide KTTKS in rat skin. J Pharm Biomed Anal. 2012. PubMed 22921149